Canopy Growth Corporation
NASDAQ:CGCDrug Manufacturers - Specialty & Generic
+$0.01 today
- Market cap
- $212.31M
- Beta
- 0.78
- P/E (TTM)
- -1.8
- EPS (TTM)
- -$0.76
Volume 3.44M
Average 9.97M
CGC Revenue
Total income from selling goods and services before any costs are deducted; the top line of the income statement.
Canopy Growth CorporationNASDAQ: CGC
Revenue · Q4 FY2025 · quarter ended Mar 2026
Revenue grows, but more slowly than its trailing trend
Q4 FY2025 revenue of CA$71.25M rose 9.6% year over year, behind the +16.1% change in trailing-twelve-month revenue. Sequentially, it fell 30.3% from the prior quarter. Over 3 fiscal years it compounded at +13.2% a year.
Context
- Revenue increased in 1 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether revenue reaches the consensus estimate from 5 analysts of CA$234.82M (-51.4%) for the fiscal year ending Mar 2027, a slowdown from the +79.8% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- CA$71.25M-30.3% QoQ
- Last fiscal yearMar 2026
- CA$483.67M+79.8% YoY
- LTMMar 2026
- CA$312.34M+16.1% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +9.6% | -19.3% | -28.9 pp |
| 1 year | +79.8% | -51.4% | -131.3 pp |
| 3-year CAGR | +13.2% | -17.8% | -31.0 pp |
| 5-year CAGR | -9.7% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Revenue history
CAD · from the income statement
- Latest · FY2025
- 483.67M CAD
- Year-over-year change
- +79.8%
- 4-year CAGR
- +0.4%
| Period | Period end | Revenue | YoY change |
|---|---|---|---|
| FY2025 | 2026-03-31 | 483.67M | +79.8% |
| FY2024 | 2025-03-31 | 269M | -9.5% |
| FY2023 | 2024-03-31 | 297.15M | -10.8% |
| FY2022 | 2023-03-31 | 333.25M | -29.9% |
| FY2021 | 2022-03-31 | 475.7M | — |
Revenue vs competitors
How CGC compares with its peers on the latest reported figures
- Peers report in different currencies, so revenue is compared through growth and rates rather than absolute size.
- Its year-over-year change of +16.1% is the 2nd highest of 8, against a peer median of -3.9%.
- Over three fiscal years its annual growth of +13.2% compares with a peer median of -0.7%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Mar 2026 | $361.51M USD | +13.8% | -10.3% | |
| LTM Mar 2026 | CA$312.34M CAD | +16.1% | +13.2% | |
| LTM Mar 2026 | CA$310.87M CAD | -9.4% | +12.8% | |
| LTM Mar 2026 | $238.26M USD | -3.9% | +2.7% | |
| LTM Mar 2026 | $135.16M USD | — | +5.0% | |
| LTM Mar 2026 | $41.8M USD | +9.3% | -0.7% | |
BIOABioAge Labs, Inc. | LTM Mar 2026 | $10.32M USD | +611.0% | — |
| LTM Mar 2026 | $8.37M USD | -52.9% | -35.9% | |
| LTM Mar 2026 | $31K USD | -52.3% | -92.5% | |
| LTM Mar 2026 | $0 USD | — | — | |
| Peer median (excluding CGC) | — | -3.9% | -0.7% | |
Competitors are the stored peer set for CGC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Mar 2022 | FY2022 Mar 2023 | FY2023 Mar 2024 | FY2024 Mar 2025 | FY2025 Mar 2026 |
|---|---|---|---|---|---|
| Revenue | 475.7M | 333.25M | 297.15M | 269M | 483.67M |
| Cost of Revenue | 663.11M | 396.78M | 216.26M | 189.48M | 386.51M |
| Gross Profit | (187.41M) | (63.53M) | 80.88M | 79.51M | 97.16M |
| Gross Margin | -39.4% | -19.1% | 27.2% | 29.6% | 20.1% |
| Research & Development | 32.26M | 21.72M | 4.61M | 1.91M | 0 |
| Selling, General & Admin | 361.1M | 297.98M | 180.59M | 121.71M | 223.11M |
| Operating Expenses | 831.39M | 2.57B | 309.6M | 196.65M | 322.6M |
| Depreciation & Amortization | 110.94M | 80.03M | 53.18M | 43.12M | 50.86M |
| EBITDA | (52.98M) | (2.88B) | (312.83M) | (479.31M) | 50.86M |
| EBITDA Margin | -11.1% | -864.2% | -105.3% | -178.2% | 10.5% |
| Operating Income | (1.02B) | (2.63B) | (228.71M) | (117.14M) | (161.66M) |
| Operating Margin | -214.2% | -789.3% | -77.0% | -43.5% | -33.4% |
| Interest Income | 6.6M | 24.28M | 16.24M | 8.82M | 10M |
| Interest Expense | 103.94M | 126.16M | 105.35M | 74.57M | 38.19M |
| Other Income / Expenses | 750.94M | (455.64M) | (242.64M) | (479.85M) | (101.23M) |
| Income Before Tax | (267.86M) | (3.09B) | (471.36M) | (597M) | (262.89M) |
| Pre-Tax Margin | -56.3% | -926.1% | -158.6% | -221.9% | -54.4% |
| Income Tax Expense | (8.95M) | (5.73M) | 12.33M | 7.14M | 23K |
| Net Income | (310.04M) | (3.28B) | (657.27M) | (598.12M) | (366.64M) |
| Net Margin | -65.2% | -983.7% | -221.2% | -222.4% | -75.8% |
| EPS (Basic) | (7.70) | (70.70) | (6.47) | (5.53) | (0.88) |
| EPS (Diluted) | (7.70) | (70.70) | (8.79) | (5.53) | (0.88) |
| Weighted Avg Shares | 39.13M | 46.37M | 101.63M | 107.55M | 2.98B |
| Weighted Avg Shares (Diluted) | 39.13M | 46.37M | 74.79M | 107.55M | 2.98B |
Canopy Growth Corporation
NASDAQ:CGC
Intrinsic Alpha fair value
Locked
Current Price
$0.50
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.